Merck & Co (MRK)
133.72
+0.91 (0.69%)
NYSE · Last Trade: Nov 21st, 4:07 AM EST
Detailed Quote
| Previous Close | 132.81 |
|---|---|
| Open | 134.33 |
| Bid | 133.50 |
| Ask | 135.74 |
| Day's Range | 133.11 - 137.17 |
| 52 Week Range | 93.90 - 156.92 |
| Volume | 15,612,004 |
| Market Cap | 338.50B |
| PE Ratio (TTM) | 136.45 |
| EPS (TTM) | 1.0 |
| Dividend & Yield | 3.400 (2.54%) |
| 1 Month Average Volume | 9,895,401 |
Chart
About Merck & Co (MRK)
Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
News & Press Releases
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the pivotal Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech, met its primary endpoint of overall survival (OS) compared to treatment of physician’s choice (TPC, consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel) in the treatment of patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy. TroFuse-015 represents the first time a TROP2-directed ADC has demonstrated an OS benefit in a global Phase 3 trial in this patient population, where there is significant unmet need. These data will be presented at an upcoming medical meeting and shared with regulatory authorities.
By Merck & Co., Inc. · Via Business Wire · November 20, 2026
One of these mRNA pioneers has the products and pipeline to drive growth.
Via The Motley Fool · November 20, 2026
Dow Jones Losers Today: NIKE and UnitedHealth Lead Declineschartmill.com
Via Chartmill · November 19, 2026
Dow Jones Decliners: UNH, NKE, CAT Lead Today's Sessionchartmill.com
Via Chartmill · November 19, 2026
Dow Jones Top Movers: Decliners Lead Nov. 18, 2026 Sessionchartmill.com
Via Chartmill · November 18, 2026
Dow Jones Losers on Nov. 3, 2026: SHW, HD and MRK Lead Declineschartmill.com
Via Chartmill · November 3, 2026
Merck & Co., Inc. (NYSE:MRK) is studying how its experimental personalized cancer vaccine might work across different tumor types, with kidney cancer data expected to help determine whether the approach can extend beyond tumors with a high number of mutations, a company executive said at the Jef
Via MarketBeat · November 19, 2026
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a research collaboration that brings together Isomorphic Labs’ AI approach to drug discovery with Merck’s rich proprietary data resources and deep discovery experience.
By Merck & Co., Inc. · Via Business Wire · November 19, 2026
Moderna's melanoma vaccine plus Keytruda cut the risk of recurrence or death by 42% in Phase 3, yet the stock sank. Here's why.
Via The Motley Fool · November 19, 2026
Dow Jones Gainers and Losers: Top Movers in Nov. 18, 2026 US Sessionchartmill.com
Via Chartmill · November 18, 2026
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Thomas H. Glocer intends to retire from the Merck Board of Directors at the Company’s Annual Meeting of Shareholders in May 2027. The independent members of the Board have appointed Douglas M. Baker, Jr., as independent lead director, effective Jan. 1, 2027, succeeding Mr. Glocer in the role.
By Merck & Co., Inc. · Via Business Wire · November 18, 2026
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL) and other hematologic malignancies in the BELLWAVE program.
By Merck & Co., Inc. · Via Business Wire · November 17, 2026
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.88 per share of the company’s common stock for the first quarter of 2027. Payment will be made on January 8, 2027, to shareholders of record at the close of business on December 15, 2026.
By Merck & Co., Inc. · Via Business Wire · November 17, 2026
The healthcare stock has surged nearly 40% this year.
Via The Motley Fool · November 16, 2026
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of an expanded indication for ENFLONSIA® (clesrovimab) to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children up to 24 months of age at increased risk for severe RSV disease through their second RSV season. The CHMP recommendation will now be reviewed by the European Commission (EC) for marketing authorization in the European Union (EU), Iceland, Liechtenstein and Norway, and a final decision is expected in the next two months.
By Merck & Co., Inc. · Via Business Wire · November 13, 2026
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. This recommendation will now be reviewed by the European Commission (EC) for marketing authorization in the European Union (EU), Iceland, Liechtenstein and Norway. A final decision is expected in the next two months.
By Merck & Co., Inc. · Via Business Wire · November 13, 2026
AbbVie, Merck and Gilead Sciences offer growing dividends alongside pipeline-driven growth, making pharmaceutical stocks a defensive option as investors seek shelter from market volatility.
Via MarketBeat · November 12, 2026
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, Nov. 19, 2026, at 11:00 a.m. GMT / 6:00 a.m. ET.
By Merck & Co., Inc. · Via Business Wire · November 12, 2026
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
Via MarketBeat · November 11, 2026
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company’s Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutide (4 mg, 7 mg and 10 mg), an investigational injectable GLP-1/glucagon receptor co-agonist, versus placebo for the treatment of adults with MASH and stage F2 or F3 liver fibrosis. The findings were presented during a late-breaking abstract session at The Liver Meeting (TLM), being held in Denver, Colo., and simultaneously published in The Lancet.
By Merck & Co., Inc. · Via Business Wire · November 9, 2026
Moderna's cancer vaccine has been the big story this year, but its latest quarter showed the rest of its business is improving, too.
Via The Motley Fool · November 6, 2026
They have both outperformed the broader equity market over the long run.
Via The Motley Fool · November 5, 2026
This dividend ETF has delivered surprisingly strong growth for the past 15 years.
Via The Motley Fool · November 4, 2026
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.
Via The Motley Fool · November 3, 2026
In 2022, the last time rates rose quickly, these stocks surged, a couple of them by more than 80%.
Via The Motley Fool · November 3, 2026
